Canaccord Genuity Reiterates Buy Rating for Aphria (APHA)

Canaccord Genuity reaffirmed their buy rating on shares of Aphria (NYSE:APHA) in a research note published on Wednesday.

Shares of APHA stock opened at $4.51 on Wednesday. Aphria has a 52-week low of $4.42 and a 52-week high of $19.87.

About Aphria

Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.

Recommended Story: How mutual funds make money

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply